Organogenesis Holdings Inc.

ORGO

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001661181

D

fourth fifth of 369 graded peers in healthcare

rank 240 of 369; percentile 64.9; sampling error 2.5 points; lower is stronger


A B C D E

D, the sloth




Scoreboard	
Profitability	E percentile 91.0
Solvency	B percentile 33.6
Growth and financing	B percentile 33.8
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $598.7M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered; fortress balance sheet not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Feb 26, 2026 260 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$0.97 2026-11-12; market equity $125.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care and surgical and sports medicine markets. Our mission is advancing healing and recovery beyond expectations. Several of our existing and pipeline products in our portfolio have Premarket Application ("PMA") approval, or 510(k) clearance from the United States Food and Drug Administration ("FDA"). Our solutions address large and growing markets driven by aging demographics and increases in comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 91.0						
Gross profitability	not computable	32.3%				

latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Accruals ratio	8.6%	(6.6%)	91.0	800	2025-12-31	
Gross margin stability, five years	not computable	2.8 pts				
latest aligned inputs end 2024-12-31; latest annual assets end 2025-12-31						
Solvency, sleeve percentile 33.6						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	5.27	(0.35)	17.6	744	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	3.62x	2.95x	49.6	826	2025-12-31	
Growth and financing, sleeve percentile 33.8						
Revenue growth, three-year compound	7.8%	10.1%	54.7	412	2025-12-31	
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	148.9%	37.1%	21.4	104	2025-12-31	
Asset growth, three years	10.0%	2.2%	31.5	694	2025-12-31	
Net share issuance, one year	1.4%	2.5%	27.5	627	2026-02-23	


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 37,277,000 USD; Altman Z is not used

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
235	Royalty Pharma plc (RPRX)	63.6	D	
236	Cardiff Oncology, Inc. (CRDF)	63.9	D	short runway, fortress balance sheet
237	Integra Lifesciences Holdings Corp. (IART)	64.1	D	
238	AbCellera Biologics Inc. (ABCL)	64.4	D	
239	Arvinas, Inc. (ARVN)	64.7	D	fortress balance sheet
240	Organogenesis Holdings Inc. (ORGO)	64.9	D	fortress balance sheet
241	AIM ImmunoTech Inc. (AIM)	65.2	D	late filer, degenerate inputs, distress
242	Entera Bio Ltd. (ENTX)	65.5	D	degenerate inputs
243	Caribou Biosciences, Inc. (CRBU)	65.8	D	short runway
244	Fulgent Genetics, Inc. (FLGT)	66.0	D	
245	Dentsply Sirona Inc. (XRAY)	66.3	D	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-12 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(67.8%)	(1.9%)	8
Distance from 52-week high	(85.1%)	(30.8%)	6
EBIT to enterprise value	26.9%	(1.9%)	98
Free cash flow yield	(19.5%)	(1.0%)	24
Book value to price	0.96	0.28	84
Sales to price	4.50	0.29	98
Composite equity issuance, five years	1.4%	20.5%	29
Relative strength against the sector, log excess return	(1.30)	(0.19)	8

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$21.3M
Operating cash flow, four quarters	$10.3M
Months of runway	not finite
Days since last periodic filing	8 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$935,110

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$366.3M	2024-12-31	2025-02-27	10-K	25-029137
2	assets	us-gaap:Assets	$497.9M	2024-12-31	2026-02-26	10-K	26-076730
3	operating income	us-gaap:OperatingIncomeLoss	$12.5M	2023-12-31	2026-02-26	10-K	26-076730
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$10.4M	2023-12-31	2026-02-26	10-K	26-076730
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$5.4M	2023-12-31	2026-02-26	10-K	26-076730
6	total debt	us-gaap:LongTermDebt	$66.6M	2023-12-31	2024-02-29	10-K	24-023150
7	book equity	us-gaap:StockholdersEquity	$278.7M	2023-12-31	2026-02-26	10-K	26-076730
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$103.8M	2023-12-31	2025-02-27	10-K	25-029137
9	total debt	us-gaap:LongTermDebt	$71.2M	2022-12-31	2023-03-01	10-K	23-005585
10	book equity	us-gaap:StockholdersEquity	$265.7M	2022-12-31	2026-02-26	10-K	26-076730
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$102.5M	2022-12-31	2024-02-29	10-K	24-023150
12	net income	us-gaap:NetIncomeLoss	$37.0M	2025-12-31	2026-02-26	10-K	26-076730
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$10.3M	2025-12-31	2026-02-26	10-K	26-076730
14	assets	us-gaap:Assets	$598.7M	2025-12-31	2026-02-26	10-K	26-076730
15	revenue	us-gaap:Revenues	$482.0M	2024-12-31	2026-02-26	10-K	26-076730
16	gross profit	us-gaap:GrossProfit	$326.7M	2023-12-31	2025-02-27	10-K	25-029137
17	revenue	us-gaap:Revenues	$433.1M	2023-12-31	2026-02-26	10-K	26-076730
18	gross profit	us-gaap:GrossProfit	$345.9M	2022-12-31	2025-02-27	10-K	25-029137

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	revenue	us-gaap:Revenues	$450.9M	2022-12-31	2025-02-27	10-K	25-029137
20	gross profit	us-gaap:GrossProfit	$353.2M	2021-12-31	2024-02-29	10-K	24-023150
21	revenue	us-gaap:Revenues	$467.4M	2021-12-31	2024-02-29	10-K	24-023150
22	gross profit	us-gaap:GrossProfit	$251.0M	2020-12-31	2023-03-01	10-K	23-005585
23	revenue	us-gaap:Revenues	$338.3M	2020-12-31	2023-03-01	10-K	23-005585
24	current assets	us-gaap:AssetsCurrent	$362.2M	2025-12-31	2026-02-26	10-K	26-076730
25	current liabilities	us-gaap:LiabilitiesCurrent	$100.1M	2025-12-31	2026-02-26	10-K	26-076730
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$3.1M	2025-12-31	2026-02-26	10-K	26-076730
27	operating income	us-gaap:OperatingIncomeLoss	$44.7M	2025-12-31	2026-02-26	10-K	26-076730
28	book equity	us-gaap:StockholdersEquity	$300.1M	2025-12-31	2026-02-26	10-K	26-076730
29	liabilities	us-gaap:Liabilities	$164.8M	2025-12-31	2026-02-26	10-K	26-076730
30	depreciation amortization	us-gaap:Depreciation	$10.4M	2023-12-31	2026-02-26	10-K	26-076730
31	interest expense	us-gaap:InterestExpense	$2.2M	2023-12-31	2024-02-29	10-K	24-023150
32	revenue	us-gaap:Revenues	$564.2M	2025-12-31	2026-02-26	10-K	26-076730
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$14.2M	2025-12-31	2026-02-26	10-K	26-076730
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$14.2M	2024-12-31	2026-02-26	10-K	26-076730
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$10.0M	2024-12-31	2026-02-26	10-K	26-076730
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$30.9M	2023-12-31	2026-02-26	10-K	26-076730
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$24.4M	2023-12-31	2026-02-26	10-K	26-076730
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$24.9M	2022-12-31	2025-02-27	10-K	25-029137
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$33.9M	2022-12-31	2025-02-27	10-K	25-029137
40	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$15.3M	2025-12-31	2026-02-26	10-K	26-076730
41	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$47.0M	2025-12-31	2026-02-26	10-K	26-076730
42	income tax	us-gaap:IncomeTaxExpenseBenefit	$9.9M	2025-12-31	2026-02-26	10-K	26-076730
43	current assets	us-gaap:AssetsCurrent	$285.9M	2024-12-31	2026-02-26	10-K	26-076730
44	current liabilities	us-gaap:LiabilitiesCurrent	$77.5M	2024-12-31	2026-02-26	10-K	26-076730
45	assets	us-gaap:Assets	$460.0M	2023-12-31	2025-02-27	10-K	25-029137
46	assets	us-gaap:Assets	$449.4M	2022-12-31	2024-02-29	10-K	24-023150
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	128,640,671	2026-02-23	2026-02-26	10-K	26-076730
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	126,853,536	2025-04-28	2025-04-29	10-K/A	25-104050

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.